Skip to main content

Ortho Biotech Products, L.P. has submitted a new drug application (NDA) to the United States Food and Drug Administration for their novel agent trabectedin to be used in combination with Doxil® (doxorubicin HCI liposome injection) for the treatment of relapsed ovarian cancer.

Trabectedin is a synthetic cytotoxic antitumor agent that was originally derived from the Caribbean sea squirt (Ecteinascidia turbinate).  Trabectedin binds to the minor groove of DNA, interfering with several DNA processes essential for sustained cellular division and survival.

The NDA for trabectedin is based on results from a Phase III trial comparing trabectedin plus Doxil with Doxil alone in women with relapsed ovarian cancer. The trabectedin arm demonstrated significantly improved progression-free survival compared with the Doxil alone.

Scroll to Continue

Recommended Articles

Image placeholder title

Kisqali Improves Survival in Premenopausal ER+ Advanced Breast Cancer

Kisqali prolongs survival for Pre-menopausal ER positive HER2 Neg breast cancer. San Antonio 2020 update.

Jemperli

GARNET Study Leads to FDA Approval for Jemperli for Uterine/Endometrial Cancer

Jemperli immunotherapy advances treatment of endometrial cancer, especially those with MSI-H or dMMR defects.